REWIND

What is REWIND?

Cardiovascular outcomes for dulaglutide in 9,901 adults with type 2 diabetes (Gerstein et al., Lancet 2019): MACE down 12% over a median 5.4 years.

Most participants had not yet had a cardiovascular event, so this was largely primary prevention, which is a harder result to get.

Related reading: REWIND: Dulaglutide in a Primary-Prevention Population

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.

Where REWIND comes up on this site

On GLP Watchdog, REWIND comes up in 1 research article.

Other terms under trial

• SURMOUNT-5
• SURMOUNT-2
• SURMOUNT-3
• SURPASS-2
• SUSTAIN-6
• PIONEER 6
• STEP-HFpEF
• EXSCEL
• ELIXA
• AMPLITUDE-O
• HARMONY OUTCOMES
• SCALE Diabetes
• STEP 2
• SUMMIT
• SCALE Maintenance

Where the evidence lives

• The full GLP-1 glossary (150 terms, 8 categories)
• Research articles — written from primary sources
• Tools and calculators
• Compare GLP-1 telehealth providers